FORT LAUDERDALE, FL, Nov. 29, 2004 (MARKET WIRE via COMTEX) -- Sunwin International Neutraceuticals, Inc. (SUWN), an industry leader in Chinese herbs, veterinary medicines and low-calorie natural sweetener in China, announced today that the Company has entered into a partnership with Shandong University of Traditional Chinese Medicine, a leading university in research and education of Chinese traditional medicine in China, to expand its efforts in research and development for new products.
Under the partnership agreement, Sunwin will set up a research fund for science and technology development at the Shandong University of Traditional Chinese Medicine with the an initial investment of US$360,000. The primary purpose for the fund is to support the research projects for the development of new medicines that have true potential commercial applications. The research projects will comprise new medicine screening, laboratory research, animal test and clinical trial for fast tracking the final clearance from the government agency for sale. The fund mainly aims at developing Chinese traditional medicines to cure the common frequently occurring diseases that significant relate to people's physical health and well being. The key is to focus on new innovations of medicines that have yet to complete the required clinical reporting, as well as the creation of a host of new applications of Chinese traditional medicine.
In addition, both parties will establish a joint venture that will manufacture and distribute animal healthy related products. Shandong University of Traditional Chinese Medicine will be responsible for providing technology while Sunwin will be responsible for organizing production, management and distribution. The major initiative is to produce the natural, environment friendly, and non-residual animal health products and feed additives.
The Company's CEO, Baozhong Yuan, noted, "We are excited with this partnership and we believe this partnership is a milestone in our company history in which we try to integrate our research and development into commercial success in a much more cost-effective and expedited manner. We believe this partnership can reduce time for commercialization of our new products substantially. This will definitely offer us a competitive advantage over any peers in the industry. This partnership will also enhance our leading position in China in production and research of Chinese traditional medicine for both human and animal utilization."
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals, Inc. ("Sunwin") is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, nutraceutical products, natural sweetener (beet sugar), and animal medicine prepared from 100% organic herbal ingredients. Sunwin International Neutraceuticals, Inc. is doing business in China through its subsidiary, Shandong Qufu Natural Green Engineering Company, Limited ("Qufu"). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumers to provide a quality, value, and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002 state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more information about Sunwin, please visit http://www.sunwin.biz.
Safe Harbor Statement
Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.